Alberto M Pereira

List of Publications by Year
in descending order

331	17,159	13068	22102
papers	citations	68 h-index	113 g-index

339	339	339	11249
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mortality in Acromegaly: A Metaanalysis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 61-67.	1.8	464
2	Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2277-2284.	1.8	324
3	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 2011, 165, 383-392.	1.9	322
4	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
5	Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2171-2180.	1.8	304
6	Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2855-2864.	1.8	285
7	Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary, 2012, 15, 71-83.	1.6	274
8	Survival and Death Causes in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 313-319.	1.8	248
9	Acromegaly. Nature Reviews Disease Primers, 2019, 5, 20.	18.1	247
10	Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease. New England Journal of Medicine, 2010, 362, 1846-1848.	13.9	233
11	MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects. European Journal of Endocrinology, 2012, 167, 311-326.	1.9	226
12	Quality of Life in Patients after Long-Term Biochemical Cure of Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3279-3286.	1.8	225
13	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology, 2009, 161, 923-931.	1.9	223
14	Treatment and Follow-Up of Clinically Nonfunctioning Pituitary Macroadenomas. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3717-3726.	1.8	216
15	Decreased Quality of Life in Patients with Acromegaly Despite Long-Term Cure of Growth Hormone Excess. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5369-5376.	1.8	213
16	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	1.8	207
17	Mortality in Patients Treated for Cushingâ€™s Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 976-981.	1.8	201
18	Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 43-51.	1.8	198

#	Article	IF	Citations
19	Observation Alone after Transsphenoidal Surgery for Nonfunctioning Pituitary Macroadenoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1796-1801.	1.8	195
20	Determinants of Survival in Treated Acromegaly in a Single Center: Predictive Value of Serial Insulin-Like Growth Factor I Measurements. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2789-2796.	1.8	188
21	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	2.6	183
22	High prevalence of long-term cardiovascular, neurological and psychosocial morbidity after treatment for craniopharyngioma. Clinical Endocrinology, 2005, 62, 197-204.	1.2	182
23	Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2731-2739.	1.8	182
24	The natural course of non-functioning pituitary macroadenomas. European Journal of Endocrinology, 2007, 156, 217-224.	1.9	175
25	Loss-of-function mutations in IGSF1 cause an X-linked syndrome of central hypothyroidism and testicular enlargement. Nature Genetics, 2012, 44, 1375-1381.	9.4	169
26	Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clinical Endocrinology, 2004, 61, 61-74.	1.2	165
27	Long-Term Predictive Value of Postsurgical Cortisol Concentrations for Cure and Risk of Recurrence in Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5858-5864.	1.8	161
28	Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3525-3532.	1.8	161
29	Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 569-576.	5.5	151
30	Diseaseâ€specific impairments in quality of life during longâ€term followâ€up of patients with different pituitary adenomas. Clinical Endocrinology, 2008, 69, 775-784.	1.2	148
31	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology, 2015, 173, R1-R14.	1.9	141
32	Subtle Cognitive Impairments in Patients with Long-Term Cure of Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2699-2714.	1.8	140
33	Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 71-75.	1.8	138
34	Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2610-2615.	1.8	136
35	A Variable Degree of Intrauterine and Postnatal Growth Retardation in a Family with a Missense Mutation in the Insulin-Like Growth Factor I Receptor. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3062-3070.	1.8	132
36	Meta-Analysis and Dose-Response Metaregression: Circulating Insulin-Like Growth Factor I (IGF-I) and Mortality. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2912-2920.	1.8	131

#	Article	IF	Citations
37	Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3348-3356.	1.8	128
38	Pituitary Dysfunction in Adult Patients after Cranial Radiotherapy: Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2330-2340.	1.8	126
39	Neuropsychiatric Disorders in Cushingâ€™s Syndrome. Neuroendocrinology, 2010, 92, 65-70.	1.2	125
40	High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. European Journal of Endocrinology, 2011, 164, 475-483.	1.9	125
41	Increased Prevalence of Psychopathology and Maladaptive Personality Traits after Long-Term Cure of Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E129-E141.	1.8	121
42	Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology, 2003, 58, 428-435.	1.2	120
43	Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3288-3296.	1.8	116
44	Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. European Journal of Endocrinology, 2010, 162, 11-18.	1.9	112
45	Quality of Life Is Decreased after Treatment for Nonfunctioning Pituitary Macroadenoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3364-3369.	1.8	111
46	Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1118-1124.	1.8	109
47	Outcome of Palliative Embolization of Bone Metastases in Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3184-3189.	1.8	106
48	Quality of life in treated adult craniopharyngioma patients. European Journal of Endocrinology, 2006, 154, 483-489.	1.9	103
49	Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3758-3762.	1.8	100
50	Reversible Diastolic Dysfunction after Long-Term Exogenous Subclinical Hyperthyroidism: A Randomized, Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6041-6047.	1.8	96
51	Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary, 2015, 18, 752-776.	1.6	95
52	The Hypercoagulable State in Cushing's Disease Is Associated with Increased Levels of Procoagulant Factors and Impaired Fibrinolysis, But Is Not Reversible after Short-Term Biochemical Remission Induced by Medical Therapy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1303-1310.	1.8	92
53	Impact of the Exon 3-Deleted Growth Hormone (GH) Receptor Polymorphism on Baseline Height and the Growth Response to Recombinant Human GH Therapy in GH-Deficient (GHD) and Non-GHD Children with Short Stature: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3721-3730.	1.8	90
54	Progression of Vertebral Fractures Despite Long-Term Biochemical Control of Acromegaly: A Prospective Follow-up Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4808-4815.	1.8	90

#	Article	IF	Citations
55	Clinical and Biochemical Characteristics of a Male Patient with a Novel Homozygous STAT5b Mutation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3482-3485.	1.8	87
56	Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. European Journal of Endocrinology, 2010, 162, 331-340.	1.9	87
57	Rituximab in relapsing Graves' disease, a phase II study. European Journal of Endocrinology, 2008, 159, 609-615.	1.9	86
58	Smaller grey matter volumes in the anterior cingulate cortex and greater cerebellar volumes in patients with long-term remission of Cushing's disease: a caseâ€“control study. European Journal of Endocrinology, 2013, 169, 811-819.	1.9	84
59	Preoperative risk factors for postoperative complications in endoscopic pituitary surgery: a systematic review. Pituitary, 2018, 21, 84-97.	1.6	84
60	Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clinical Endocrinology, 2006, 66, 061109020454001-???.	1.2	83
61	The IGSF1 Deficiency Syndrome: Characteristics of Male and Female Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4942-4952.	1.8	81
62	The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. European Journal of Endocrinology, 2007, 156, 455-462.	1.9	80
63	MANAGEMENT OF ENDOCRINE DISEASE: Mortality remains increased in Cushing's disease despite biochemical remission: a systematic review and meta-analysis. European Journal of Endocrinology, 2015, 172, R143-R149.	1.9	80
64	An Activating Mutation in the Kinase Homology Domain of the Natriuretic Peptide Receptor-2 Causes Extremely Tall Stature Without Skeletal Deformities. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1988-E1998.	1.8	78
65	Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e32-e41.	1.8	78
66	Negative illness perceptions are associated with impaired quality of life in patients after long-term remission of Cushing's syndrome. European Journal of Endocrinology, 2011, 165, 527-535.	1.9	77
67	Widespread reductions of white matter integrity in patients with long-term remission of Cushing's disease. NeuroImage: Clinical, 2014, 4, 659-667.	1.4	76
68	The Quantification of Gluconeogenesis in Healthy Men by 2H2O and [2-13C]Glycerol Yields Different Results: Rates of Gluconeogenesis in Healthy Men Measured with 2H2O Are Higher Than Those Measured with [2-13C]Glycerol. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2220-2226.	1.8	76
69	Therapy of Endocrine disease: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. European Journal of Endocrinology, 2013, 169, R1-R14.	1.9	74
70	Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. European Journal of Endocrinology, 2008, 159, 363-367.	1.9	71
71	Endoscopic vs. microscopic transsphenoidal surgery for Cushingâ€™s disease: a systematic review and meta-analysis. Pituitary, 2018, 21, 524-534.	1.6	71
72	High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a caseâ€“control study. European Journal of Endocrinology, 2009, 160, 357-365.	1.9	70

#	Article	IF	Citations
73	Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3550-3558.	1.8	69
74	IGSF1 Deficiency: Lessons From an Extensive Case Series and Recommendations for Clinical Management. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1627-1636.	1.8	68
75	Coping Strategies in Patients after Treatment for Functioning or Nonfunctioning Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 964-971.	1.8	67
76	Opioids and Their Endocrine Effects: A Systematic Review and Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1020-1029.	1.8	66
77	Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 2004, 150, 489-495.	1.9	65
78	Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clinical Endocrinology, 2008, 69, 123-128.	1.2	65
79	No Correlation between A(â€“1438)G Polymorphism in 5-HT2A Receptor Gene Promoter and the Density of Frontal Cortical 5-HT2A Receptors in Schizophrenia. Human Heredity, 1999, 49, 103-105.	0.4	63
80	Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial. Clinical Endocrinology, 2006, 64, 284-291.	1.2	63
81	Increased Psychopathology and Maladaptive Personality Traits, But Normal Cognitive Functioning, In Patients after Long-Term Cure of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E392-E402.	1.8	63
82	Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters. Frontiers in Endocrinology, 2017, 8, 40.	1.5	63
83	Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. European Journal of Endocrinology, 2012, 166, 27-34.	1.9	62
84	Effects of Dehydroepiandrostenedione, Superimposed on Growth Hormone Substitution, on Quality of Life and Insulin-Like Growth Factor I in Patients with Secondary Adrenal Insufficiency: A Randomized, Placebo-Controlled, Cross-Over Trial. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3295-3303.	1.8	61
85	Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: cross-sectional study and review of the literature. European Journal of Endocrinology, 2014, 171, 171-182.	1.9	61
86	Effectiveness of medical treatment for Cushingâ€™s syndrome: a systematic review and meta-analysis. Pituitary, 2018, 21, 631-641.	1.6	61
87	Malignant prolactinoma: case report and review of the literature. European Journal of Endocrinology, 2006, 155, 523-534.	1.9	60
88	Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia, 2008, 51, 1581-1593.	2.9	60
89	Copy number variants in patients with short stature. European Journal of Human Genetics, 2014, 22, 602-609.	1.4	60
90	Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. European Journal of Endocrinology, 2011, 165, 225-231.	1.9	59

#	Article	IF	Citations
91	Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clinical Endocrinology, 2006, 64, 617-624.	1.2	57
92	Metabolic Profile in Growth Hormone-Deficient (GHD) Adults after Long-Term Recombinant Human Growth Hormone (rhGH) Therapy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 352-361.	1.8	57
93	Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. European Journal of Endocrinology, 2006, 154, 525-531.	1.9	54
94	Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Hormone and IGF Research, 2010, 20, 226-233.	0.5	54
95	Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2â€year followâ€up study. Clinical Endocrinology, 2012, 77, 99-105.	1.2	54
96	Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma. Pituitary, 2007, 10, 61-65.	1.6	53
97	High mortality within 90 days of diagnosis in patients with Cushingâ€™s syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	1.9	53
98	A longâ€term followâ€up study of eighteen patients with thyrotrophinâ€secreting pituitary adenomas. Clinical Endocrinology, 2014, 80, 395-402.	1.2	52
99	Towards a better quality of life (QoL) for patients with pituitary diseases: results from a focus group study exploring QoL. Pituitary, 2015, 18, 86-100.	1.6	51
100	Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. European Journal of Endocrinology, 2017, 176, 339-347.	1.9	51
101	Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Pituitary, 2007, 10, 237-249.	1.6	50
102	Thyrotropin Secretion Profiles Are Not Different in Men and Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3964-3967.	1.8	50
103	Patients Previously Treated for Nonfunctioning Pituitary Macroadenomas Have Disturbed Sleep Characteristics, Circadian Movement Rhythm, and Subjective Sleep Quality. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1524-1532.	1.8	50
104	GH replacement therapy in elderly GH-deficient patients: a systematic review. European Journal of Endocrinology, 2011, 164, 657-665.	1.9	50
105	Postoperative diabetes insipidus: how to define and grade this complication?. Pituitary, 2021, 24, 284-291.	1.6	50
106	Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clinical Endocrinology, 2004, 60, 568-575.	1.2	49
107	Influence of the d3-Growth Hormone (GH) Receptor Isoform on Short-Term and Long-Term Treatment Response to GH Replacement in GH-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2828-2834.	1.8	49
108	Cognitive functioning and quality of life in patients with Hashimoto thyroiditis on long-term levothyroxine replacement. Endocrine, 2018, 62, 136-143.	1.1	49

#	Article	IF	Citations
109	Quality of life is decreased in female patients treated for microprolactinoma. European Journal of Endocrinology, 2007, 157, 133-139.	1.9	48
110	The effects of high fat diet on the basal activity of the hypothalamusâ€“pituitaryâ€“adrenal axis in mice. Journal of Endocrinology, 2012, 214, 191-197.	1.2	48
111	ACTH-producing pheochromocytoma: Clinical considerations and concise review of the literature. European Journal of Internal Medicine, 2009, 20, 682-685.	1.0	46
112	Acromegaly Is Associated with an Increased Prevalence of Colonic Diverticula: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2073-2079.	1.8	46
113	Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study. European Journal of Endocrinology, 2012, 167, 235-244.	1.9	46
114	Bexarotene-Induced Hypothyroidism: Bexarotene Stimulates the Peripheral Metabolism of Thyroid Hormones. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2496-2499.	1.8	45
115	Genetic Analysis of Short Children with Apparent Growth Hormone Insensitivity. Hormone Research in Paediatrics, 2012, 77, 320-333.	0.8	45
116	Preoperative Normalization of Cortisol Levels in Cushing's Disease After Medical Treatment: Consequences for Somatostatin and Dopamine Receptor Subtype Expression and In Vitro Response to Somatostatin Analogs and Dopamine Agonists. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1880-E1890.	1.8	44
117	Resting-State Functional Connectivity in Patients with Long-Term Remission of Cushingâ€™s Disease. Neuropsychopharmacology, 2015, 40, 1888-1898.	2.8	44
118	The Effects of Carbohydrate Variation in Isocaloric Diets on Glycogenolysis and Gluconeogenesis in Healthy Men. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1963-1967.	1.8	44
119	Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. European Journal of Endocrinology, 2006, 155, 701-708.	1.9	43
120	Differences in Atherosclerotic Plaque Burden and Morphology Between Type 1 and 2 Diabetes as Assessed by Multislice Computed Tomography. Diabetes Care, 2009, 32, 1507-1512.	4.3	43
121	Arthropathy in long-term cured acromeagaly is characterised by osteophytes without joint space narrowing: a comparison with generalised osteoarthritis. Annals of the Rheumatic Diseases, 2011, 70, 320-325.	0.5	43
122	Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clinical Endocrinology, 2003, 58, 288-295.	1.2	42
123	Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Hormone and IGF Research, 2006, 16, 101-107.	0.5	42
124	Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly. American Journal of Physiology - Endocrinology and Metabolism, 2004, 286, E25-E30.	1.8	41
125	5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet, The, 1997, 349, 1815.	6.3	40
126	The type 2 deiodinase Thr92Ala polymorphism is associated with increased bone turnover and decreased femoral neck bone mineral density. Journal of Bone and Mineral Research, 2010, 25, 1385-1391.	3.1	40

#	Article	IF	Citations
127	Altered neural processing of emotional faces in remitted Cushing's disease. Psychoneuroendocrinology, 2015, 59, 134-146.	1.3	40
128	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. European Journal of Endocrinology, 2016, 174, 651-662.	1.9	40
129	Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary, 2009, 12, 339-346.	1.6	39
130	The phenotype of SDHB germline mutation carriers: a nationwide study. European Journal of Endocrinology, 2017, 177, 115-125.	1.9	38
131	Enhanced self-efficacy after a self-management programme in pituitary disease: a randomized controlled trial. European Journal of Endocrinology, 2017, 177, 59-72.	1.9	38
132	The epidemiology of aggressive pituitary tumors (and its challenges). Reviews in Endocrine and Metabolic Disorders, 2020, 21, 209-212.	2.6	38
133	Thyrotropin Secretion in Mild and Severe Primary Hypothyroidism Is Distinguished by Amplified Burst Mass and Basal Secretion with Increased Spikiness and Approximate Entropy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 928-934.	1.8	37
134	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37
135	Update in prolactinomas. Netherlands Journal of Medicine, 2010, 68, 104-12.	0.6	36
136	Identification of a selective glucocorticoid receptor modulator that prevents both dietâ€induced obesity and inflammation. British Journal of Pharmacology, 2016, 173, 1793-1804.	2.7	35
137	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. Journal of Internal Medicine, 2020, 288, 168-182.	2.7	35
138	Association of the M1VPRKAR1AMutation with Primary Pigmented Nodular Adrenocortical Disease in Two Large Families. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 338-342.	1.8	34
139	Increased Daytime Somnolence despite Normal Sleep Patterns in Patients Treated for Nonfunctioning Pituitary Macroadenoma. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3898-3903.	1.8	33
140	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. Clinical Endocrinology, 2008, 69, 769-774.	1.2	33
141	Increased aortic root diameters in patients with acromegaly. European Journal of Endocrinology, 2008, 159, 97-103.	1.9	33
142	The Exon-3 Deleted Growth Hormone Receptor Polymorphism Predisposes to Long-Term Complications of Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4671-4678.	1.8	33
143	Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing's syndrome. European Journal of Endocrinology, 2009, 161, 695-703.	1.9	33
144	Alterations in diurnal rhythmicity in patients treated for nonfunctioning pituitary macroadenoma: a controlled study and literature review. European Journal of Endocrinology, 2014, 171, 217-228.	1.9	33

#	Article	IF	Citations
145	Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormone and IGF Research, 2005, 15, 200-206.	0.5	32
146	Pretreatment Insulin-Like Growth Factor-I Concentrations Predict Radiographic Osteoarthritis in Acromegalic Patients with Long-Term Cured Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2374-2379.	1.8	32
147	Drawings Reflect a New Dimension of the Psychological Impact of Long-Term Remission of Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3123-3131.	1.8	32
148	Hypothalamicâ€Pituitaryâ€Adrenal Axis Functioning in Huntington's Disease and its Association with Depressive Symptoms and Suicidality. Journal of Neuroendocrinology, 2015, 27, 234-244.	1.2	32
149	Glucocorticoid Sexual Dimorphism in Metabolism: Dissecting the Role of Sex Hormones. Trends in Endocrinology and Metabolism, 2020, 31, 357-367.	3.1	32
150	Association of interferon-Î³ and interleukin 10 genotypes and serum levels with partial clinical remission in type 1 diabetes. Clinical and Experimental Immunology, 2006, 145, 480-484.	1.1	31
151	Work disability and its determinants in patients with pituitary tumor-related disease. Pituitary, 2018, 21, 593-604.	1.6	31
152	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
153	The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary, 2016, 19, 293-302.	1.6	30
154	Thyrotropin Secretion by Thyrotropinomas Is Characterized by Increased Pulse Frequency, Delayed Diurnal Rhythm, Enhanced Basal Secretion, Spikiness, and Disorderliness. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4052-4057.	1.8	29
155	Effects of up to 15 years of recombinant human <scp>GH</scp> (rh<scp>GH</scp>) replacement on bone metabolism in adults with Growth Hormone Deficiency (<scp>GHD</scp>): The Leiden Cohort Study. Clinical Endocrinology, 2014, 81, 727-735.	1.2	29
156	Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours. Radiotherapy and Oncology, 2014, 113, 102-107.	0.3	29
157	STAT5B mutations in heterozygous state have negative impact on height: another clue in human stature heritability. European Journal of Endocrinology, 2015, 173, 291-296.	1.9	29
158	How non-functioning pituitary adenomas can affect health-related quality of life: a conceptual model and literature review. Pituitary, 2018, 21, 208-216.	1.6	29
159	Irregular and Frequent Cortisol Secretory Episodes with Preserved Diurnal Rhythmicity in Primary Adrenal Cushingâ€™s Syndrome. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1570-1577.	1.8	28
160	Thyrotropin Secretion in Healthy Subjects Is Robust and Independent of Age and Gender, and Only Weakly Dependent on Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 570-578.	1.8	28
161	Pituitary Magnetic Resonance Imaging Is Not Required in the Postoperative Follow-Up of Acromegalic Patients with Long-Term Biochemical Cure after Transsphenoidal Surgery. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4320-4324.	1.8	27
162	Growth hormone secretion and immunological function of a male patient with a homozygous STAT5b mutation. European Journal of Endocrinology, 2007, 156, 155-165.	1.9	27

#	Article	IF	Citations
163	Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma. Clinical Endocrinology, 2008, 68, 605-609.	1.2	27
164	Costâ€“effectiveness of lanreotide Autogel‹sup›Â®‹/sup›in treatment algorithms of acromegaly. Expert Review of Pharmacoeconomics and Outcomes Research, 2009, 9, 223-234.	0.7	27
165	Usefulness of Carotid Intima-Media Thickness in Patients With Diabetes Mellitus as a Predictor of Coronary Artery Disease. American Journal of Cardiology, 2009, 104, 1041-1046.	0.7	27
166	Patients With Adrenal Insufficiency Hate Their Medication: Concerns and Stronger Beliefs About the Necessity of Hydrocortisone Intake Are Associated With More Negative Illness Perceptions. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3668-3676.	1.8	27
167	Chronic Central Serous Chorioretinopathy as a Presenting Symptom of Cushing Syndrome. European Journal of Ophthalmology, 2016, 26, 442-448.	0.7	27
168	Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice. Endocrinology, 2018, 159, 3925-3936.	1.4	27
169	Improvement but no normalization of quality of life and cognitive functioning after treatment for Cushingâ€™s syndrome. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5325-5337.	1.8	27
170	Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease. Clinical Endocrinology, 2004, 60, 765-772.	1.2	26
171	Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushingâ€™s disease. Pituitary, 2013, 16, 536-544.	1.6	26
172	Non-invasive assessment of microcirculation by sidestream dark field imaging as a marker of coronary artery disease in diabetes. Diabetes and Vascular Disease Research, 2013, 10, 123-134.	0.9	26
173	Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists. European Journal of Internal Medicine, 2009, 20, 387-393.	1.0	25
174	Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging. European Journal of Endocrinology, 2010, 163, 435-441.	1.9	25
175	Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study. Pituitary, 2014, 17, 44-52.	1.6	25
176	The current landscape of European registries for rare endocrine conditions. European Journal of Endocrinology, 2019, 180, 89-98.	1.9	25
177	Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly. European Journal of Endocrinology, 2005, 153, 231-238.	1.9	24
178	Pharmacologic Therapies for Acromegaly. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2005, 4, 43-53.	1.8	24
179	Current pharmacotherapy for acromegaly: a review. Expert Opinion on Pharmacotherapy, 2005, 6, 2393-2405.	0.9	24
180	Mild cognitive deficits in patients with primary adrenal insufficiency. Psychoneuroendocrinology, 2016, 63, 170-177.	1.3	24

#	Article	IF	Citations
181	Microscopic versus endoscopic transsphenoidal surgery in the Leiden cohort treated for Cushingâ€™s disease: surgical outcome, mortality, and complications. Orphanet Journal of Rare Diseases, 2019, 14, 64.	1.2	24
182	Effects of Long-Term Endogenous Corticosteroid Exposure on Brain Volume and Glial Cells in the AdKO Mouse. Frontiers in Neuroscience, 2021, 15, 604103.	1.4	24
183	Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. European Journal of Endocrinology, 2020, 183, 427-437.	1.9	24
184	Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. European Journal of Endocrinology, 2005, 152, 53-60.	1.9	23
185	Retinoic acid receptor and retinoid X receptor subtype expression for the differential diagnosis of thyroid neoplasms. European Journal of Endocrinology, 2009, 160, 631-638.	1.9	23
186	Effects of High Fat Diet on the Basal Activity of the Hypothalamus-Pituitary-Adrenal Axis in Mice: A Systematic Review. Hormone and Metabolic Research, 2011, 43, 899-906.	0.7	23
187	Determinants of Altered Sleep-Wake Rhythmicity in Patients Treated for Nonfunctioning Pituitary Macroadenomas. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4497-4505.	1.8	23
188	Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. European Journal of Endocrinology, 2015, 173, 269-273.	1.9	23
189	Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. Journal of Bone and Mineral Research, 2020, 36, 1729-1738.	3.1	23
190	Longâ€term effects of glucocorticoid excess on the brain. Journal of Neuroendocrinology, 2022, 34, .	1.2	23
191	Pituitary Hormone Secretion Profiles in IGSF1 Deficiency Syndrome. Neuroendocrinology, 2016, 103, 408-416.	1.2	22
192	Cushingâ€™s Syndrome and Hypothalamicâ€“Pituitaryâ€“Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. Frontiers in Endocrinology, 2018, 9, 39.	1.5	22
193	IGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunction. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e70-e84.	1.8	22
194	Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test. European Journal of Endocrinology, 2015, 172, 583-593.	1.9	21
195	Increased Hair Cortisol Concentrations and BMI in Patients With Pituitary-Adrenal Disease on Hydrocortisone Replacement. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2456-2462.	1.8	21
196	DIAGNOSIS OF ENDOCRINE DISEASE: Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis. European Journal of Endocrinology, 2016, 175, R247-R253.	1.9	21
197	Pre-operative serum inflammation-based scores in patients with pituitary adenomas. Pituitary, 2021, 24, 334-350.	1.6	21
198	European Reference Networks: challenges and opportunities. Journal of Community Genetics, 2021, 12, 217-229.	0.5	21

#	Article	IF	Citations
199	Nanomedicines in the treatment of acromegaly: focus on pegvisomant. International Journal of Nanomedicine, 2006, 1, 385-398.	3.3	21
200	GH deficiency in patients irradiated for acromegaly: significance of GH stimulatory tests in relation to the 24 h GH secretion. European Journal of Endocrinology, 2006, 154, 851-858.	1.9	20
201	Cortisol Production Rate Is Similarly Elevated in Obese Women with or without the Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3318-3324.	1.8	20
202	Treatment of nonfunctioning pituitary adenomas: What were the contributions of the last 10years? A critical view. Annales D'Endocrinologie, 2012, 73, 111-116.	0.6	20
203	Intraoperative Identification of a Normal Pituitary Gland and an Adenoma Using Near-Infrared Fluorescence Imaging and Low-Dose Indocyanine Green. Operative Neurosurgery, 2016, 12, 260-268.	0.4	20
204	Mild deficits in attentional control in patients with the <scp>IGSF</scp>1 deficiency syndrome. Clinical Endocrinology, 2016, 84, 896-903.	1.2	20
205	Peptide hormone analysis in diagnosis and treatment of Differences of Sex Development: joint position paper of EU COST Action â€˜DSDnetâ€™ and European Reference Network on Rare Endocrine Conditions. European Journal of Endocrinology, 2020, 182, P1-P15.	1.9	20
206	Cognitive impairment and psychopathology in patients with pituitary diseases. Netherlands Journal of Medicine, 2012, 70, 255-60.	0.6	20
207	Automated image analysis of hand radiographs reveals widened joint spaces in patients with long-term control of acromegaly: relation to disease activity and symptoms. European Journal of Endocrinology, 2012, 166, 407-413.	1.9	19
208	Relationship between insulin-like growth factor-1 and radiographic disease in patients with primary osteoarthritis: a systematic review. Osteoarthritis and Cartilage, 2012, 20, 79-86.	0.6	19
209	Relationship between left ventricular diastolic function and arterial stiffness in asymptomatic patients with diabetes mellitus. International Journal of Cardiovascular Imaging, 2013, 29, 609-616.	0.7	19
210	Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. European Journal of Endocrinology, 2014, 170, 181-191.	1.9	19
211	More concerns and stronger beliefs about the necessity of medication in patients with acromegaly are associated with negative illness perceptions and impairment in quality of life. Growth Hormone and IGF Research, 2015, 25, 219-226.	0.5	19
212	How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary, 2018, 21, 310-322.	1.6	19
213	The partnerâ€™s perspective of the impact of pituitary disease: Looking beyond the patient. Journal of Health Psychology, 2019, 24, 1687-1697.	1.3	19
214	Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 577-587.	1.8	19
215	Serum Inflammation-based Scores in Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3796-e3819.	1.8	19
216	Toward Value Based Health Care in pituitary surgery: application of a comprehensive outcome set in perioperative care. European Journal of Endocrinology, 2019, 181, 375-387.	1.9	19

#	Article	IF	Citations
217	Acromegalic arthropathy in various stages of the disease: an MRI study. European Journal of Endocrinology, 2017, 176, 779-790.	1.9	18
218	Characteristics and Mortality of Pneumocystis Pneumonia in Patients With Cushingâ€™s Syndrome: A Plea for Timely Initiation of Chemoprophylaxis. Open Forum Infectious Diseases, 2017, 4, ofx002.	0.4	18
219	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. Acta Ophthalmologica, 2019, 97, e572-e579.	0.6	18
220	Feasibility, safety, and outcomes of a stratified fast-track care trajectory in pituitary surgery. Endocrine, 2020, 69, 175-187.	1.1	18
221	Recombinant human GH replacement increases CD34+ cells and improves endothelial function in adults with GH deficiency. European Journal of Endocrinology, 2008, 159, 105-111.	1.9	17
222	Update on the withdrawal of dopamine agonists in patients with hyperprolactinemia. Current Opinion in Endocrinology, Diabetes and Obesity, 2011, 18, 264-268.	1.2	17
223	Low Incidence of Adrenal Insufficiency after Transsphenoidal Surgery in Patients with Acromegaly: A Long-Term Follow-Up Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1163-E1170.	1.8	17
224	Endoscopic Surgery for Pituitary Tumors. Endocrinology and Metabolism Clinics of North America, 2020, 49, 487-503.	1.2	17
225	Progression of acromegalic arthropathy in long-term controlled acromegaly patients: 9 years of longitudinal follow-up. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 188-200.	1.8	17
226	Manifesto for the current understanding and management of traumatic brain injury-induced hypopituitarism. Journal of Endocrinological Investigation, 2011, 34, 541-3.	1.8	17
227	Therapeutic options in the management of acromegaly: focus on lanreotide Autogel®. Biologics: Targets and Therapy, 2008, 2, 463.	3.0	16
228	Endothelial Dysfunction in Diabetic Patients with Abnormal Myocardial Perfusion in the Absence of Epicardial Obstructive Coronary Artery Disease. Journal of Nuclear Medicine, 2009, 50, 1980-1986.	2.8	16
229	Comparison of the cortisol responses to testing with two doses of ACTH in patients with suspected adrenal insufficiency. European Journal of Endocrinology, 2011, 164, 83-87.	1.9	16
230	Administration route-dependent effects of estrogens on IGF-I levels during fixed GH replacement in women with hypopituitarism. European Journal of Endocrinology, 2007, 157, 709-716.	1.9	15
231	High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma. PLoS ONE, 2014, 9, e90602.	1.1	15
232	Quality of life in patients with adrenal insufficiency correlates stronger with hydrocortisone dosage, than with long-term systemic cortisol levels. Psychoneuroendocrinology, 2016, 72, 80-86.	1.3	15
233	Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2020, 15, 144.	1.2	15
234	Aminophylline stimulates insulin secretion in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 2001, 50, 1030-1035.	1.5	14

#	Article	IF	Citations
235	Disordered and Increased Adrenocorticotropin Secretion with Diminished Adrenocorticotropin Potency in Obese in Premenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2991-2997.	1.8	14
236	Pituitary-hormone secretion by thyrotropinomas. Pituitary, 2009, 12, 200-210.	1.6	14
237	Two phenotypes of arthropathy in long-term controlled acromegaly? A comparison between patients with and without joint space narrowing (JSN). Growth Hormone and IGF Research, 2013, 23, 159-164.	0.5	14
238	Corticosteroid use and mortality risk in patients with perforated colonic diverticular disease: a population-based cohort study. BMJ Open Gastroenterology, 2017, 4, e000136.	1.1	14
239	Early postoperative HPA-axis testing after pituitary tumor surgery: reliability and safety of basal cortisol and CRH test. Endocrine, 2020, 67, 161-171.	1.1	14
240	Both Transient and Continuous Corticosterone Excess Inhibit Atherosclerotic Plaque Formation in APOE*3-Leiden.CETP Mice. PLoS ONE, 2013, 8, e63882.	1.1	14
241	The incidence of adrenal crisis in the postoperative period of HPA axis insufficiency after surgical treatment for Cushingâ€™s syndrome. European Journal of Endocrinology, 2019, 181, 201-210.	1.9	14
242	Sex Differences in Presentation but Not in Outcome for ACTH-Dependent Cushing's Syndrome. Frontiers in Endocrinology, 2019, 10, 580.	1.5	13
243	The EuRRECa Project as a Model for Data Access and Governance Policies for Rare Disease Registries That Collect Clinical Outcomes. International Journal of Environmental Research and Public Health, 2020, 17, 8743.	1.2	13
244	CPMSâ€“improving patient care in Europe via virtual case discussions. Endocrine, 2021, 71, 549-554.	1.1	13
245	Treatment strategies for acromegaly. Expert Opinion on Emerging Drugs, 2005, 10, 875-890.	1.0	12
246	The use of an early postoperative CRH test to assess adrenal function after transsphenoidal surgery for pituitary adenomas. Pituitary, 2012, 15, 436-444.	1.6	12
247	Glucocorticoid excess induces long-lasting changes in body composition in male C57Bl/6J mice only with high-fat diet. Physiological Reports, 2013, 1, e00103.	0.7	12
248	Vascular Health in Patients in Remission of Cushing's Syndrome Is Comparable With That in BMI-Matched Controls. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4142-4150.	1.8	12
249	Cortical thickness abnormalities in long-term remitted Cushingâ€™s disease. Translational Psychiatry, 2020, 10, 293.	2.4	12
250	Role of radiotherapy in the management of acromegaly. Expert Review of Endocrinology and Metabolism, 2006, 1, 449-460.	1.2	10
251	Somatostatin analog treatment is associated with an increased sleep latency in patients with long-term biochemical remission of acromegaly. Growth Hormone and IGF Research, 2008, 18, 446-453.	0.5	10
252	Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls. European Journal of Endocrinology, 2008, 159, 705-712.	1.9	10

#	Article	IF	Citations
253	Relationship between vascular stiffness and stress myocardial perfusion imaging in asymptomatic patients with diabetes. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2050-2057.	3.3	10
254	SF-12 or SF-36 in pituitary disease? Toward concise and comprehensive patient-reported outcomes measurements. Endocrine, 2020, 70, 123-133.	1.1	10
255	Central serous chorioretinopathy in active endogenous Cushingâ€™s syndrome. Scientific Reports, 2021, 11, 2748.	1.6	10
256	Growth hormone secretion in primary adrenal Cushing's syndrome is disorderly and inversely correlated with body mass index. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E63-E70.	1.8	9
257	Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency. British Journal of Clinical Pharmacology, 2006, 61, 451-455.	1.1	9
258	Attenuated pulse size, disorderly growth hormone and prolactin secretion with preserved nyctohemeral rhythm distinguish irradiated from surgically treated acromegaly patients. Clinical Endocrinology, 2007, 66, 070115055241003.	1.2	9
259	The role of pegvisomant in the treatment of acromegaly. Expert Opinion on Biological Therapy, 2008, 8, 691-704.	1.4	9
260	Hormone Secretion by Pituitary Adenomas Is Characterized by Increased Disorderliness and Spikiness but More Regular Pulsing. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3836-3844.	1.8	9
261	Impact of Adiposity and Fat Distribution on the Dynamics of Adrenocorticotropin and Cortisol Rhythms. Current Obesity Reports, 2014, 3, 387-395.	3.5	9
262	Effects of discontinuation of growth hormone replacement in adult GH-deficient patients: a cohort study and a systematic review of the literature. European Journal of Endocrinology, 2016, 174, 705-716.	1.9	9
263	Healthcare utilization and costs among patients with non-functioning pituitary adenomas. Endocrine, 2019, 64, 330-340.	1.1	9
264	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in female mice. Aging Cell, 2021, 20, e13474.	3.0	9
265	An overview of clinical activities in Endo-ERN: the need for alignment of future network criteria. European Journal of Endocrinology, 2020, 183, 141-148.	1.9	9
266	State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1225-1238.	1.8	9
267	Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery. Pituitary, 2022, 25, 587-601.	1.6	9
268	A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease. Clinical Endocrinology, 2006, 64, 060222010233007.	1.2	8
269	Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2675-2682.	1.8	8
270	SALIVARY ALPHA-AMYLASE LEVELS MAY CORRELATE WITH CENTRAL SEROUS CHORIORETINOPATHY ACTIVITY. Retina, 2021, 41, 2479-2484.	1.0	8

#	Article	IF	Citations
271	Clinical Unmet Needs in the Treatment of Adrenal Crisis: Importance of the Patientâ€™s Perspective. Frontiers in Endocrinology, 2021, 12, 701365.	1.5	8
272	Gene expression changes in the brain of a Cushing's syndrome mouse model. Journal of Neuroendocrinology, 2022, 34, e13124.	1.2	8
273	Current clinical practice for thromboprophylaxis management in patients with Cushingâ€™s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2022, 17, 178.	1.2	8
274	Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. European Journal of Endocrinology, 2014, 170, 263-272.	1.9	7
275	Long-term effects of treatment of pituitary adenomas. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 124, 361-371.	1.0	7
276	A Patient (46XX) With Congenital Adrenal Hyperplasia and Prostate Cancer: A Case Report. Journal of the Endocrine Society, 2017, 1, 1213-1216.	0.1	7
277	Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study. Pituitary, 2020, 23, 417-429.	1.6	7
278	Introduction to Endo-ERNâ€“scope and mission. Endocrine, 2021, 71, 537-538.	1.1	7
279	Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3300-e3311.	1.8	7
280	The PRolaCT studies â€”Âa study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. Trials, 2021, 22, 653.	0.7	7
281	Hypophysitis: A comprehensive overview. Presse Medicale, 2021, 50, 104076.	0.8	7
282	Height Gain with Combined Growth Hormone and Gonadotropin-Releasing Hormone Analog Therapy in Two Pubertal Siblings with a Growth Hormone-Releasing Hormone Receptor Mutation. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 204-207.	1.8	6
283	Decreased Aerobic Exercise Capacity After Long-Term Remission From Cushing Syndrome: Exploration of Mechanisms. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1408-e1418.	1.8	6
284	Variants of FOXO3 and RPA3 genes affecting IGF-1 levels alter the risk of development of primary osteoarthritis. European Journal of Endocrinology, 2021, 184, 29-39.	1.9	6
285	Potential associations between immune signaling genes, deactivated microglia, and oligodendrocytes and cortical gray matter loss in patients with long-term remitted Cushingâ€™s disease. Psychoneuroendocrinology, 2021, 132, 105334.	1.3	6
286	Three percent annually on systemic glucocorticoids: facts, worries and perspectives. European Journal of Endocrinology, 2019, 181, C23-C28.	1.9	6
287	Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and symptomatic osteoarthritis in women. Annals of the Rheumatic Diseases, 2014, 73, 433-436.	0.5	5
288	Total score or subscales in scoring the acromegaly quality of life questionnaire: using novel confirmatory methods to compare scoring options. European Journal of Endocrinology, 2015, 173, 37-42.	1.9	5

#	Article	IF	Citations
289	Decrease in scale invariance of activity fluctuations with aging and in patients with suprasellar tumors. Chronobiology International, 2018, 35, 368-377.	0.9	5
290	Hair cortisol concentrations in chronic central serous chorioretinopathy. Acta Ophthalmologica, 2020, 98, 390-395.	0.6	5
291	Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. Pituitary, 2021, 24, 79-95.	1.6	5
292	Conditioning cortisol in healthy young women â€“ A randomized controlled trial. Psychoneuroendocrinology, 2021, 124, 105081.	1.3	5
293	68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. European Journal of Hybrid Imaging, 2020, 4, 4.	0.6	5
294	Clinical and radiographic assessment of peripheral joints in controlled acromegaly. Pituitary, 2022, 25, 622-635.	1.6	5
295	Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay. Nuclear Medicine Communications, 2007, 28, 123-127.	0.5	4
296	Outcome of complications in acromegaly patients after long-term disease remission. Expert Review of Endocrinology and Metabolism, 2015, 10, 499-510.	1.2	4
297	Response to Letter to the Editor: â€œSurgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysisâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3040-e3041.	1.8	4
298	Patients with rare endocrine conditions have corresponding views on unmet needs in clinical research. Endocrine, 2021, 71, 561-568.	1.1	4
299	Adrenal Vein Sampling in a Patient With Primary Hyperaldosteronism and Severe Contrast Allergy. Journal of the Endocrine Society, 2021, 5, bvab122.	0.1	4
300	Impact of patient-reported nasal symptoms on quality of life after endoscopic pituitary surgery: a prospective cohort study. Pituitary, 2022, 25, 308-320.	1.6	4
301	Towards a pituitary apoplexy classification based on clinical presentation and patient journey. Endocrine, 2022, 76, 132-141.	1.1	4
302	The Role of the Suprachiasmatic Nucleus in Cardiac Autonomic Control during Sleep. PLoS ONE, 2016, 11, e0152390.	1.1	3
303	Educational and knowledge gaps within the European reference network on rare endocrine conditions. Endocrine Connections, 2021, 10, 37-44.	0.8	3
304	Access to patient oriented informationâ€”a baseline Endo-ERN survey among patients with rare endocrine disorders. Endocrine, 2021, 71, 542-548.	1.1	3
305	Low prevalence of neuropathic-like pain symptoms in long-term controlled acromegaly. Pituitary, 2022, 25, 229-237.	1.6	3
306	The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone. BMJ Open, 2021, 11, e054405.	0.8	3

#	Article	IF	Citations
307	Indomethacin Does Not Affect Endogenous Glucose Production in Type 2 Diabetes Mellitus. Hormone and Metabolic Research, 2001, 33, 659-663.	0.7	2
308	Mild cognitive deficits in patients on stable treatment for primary adrenal insufficiency. Psychoneuroendocrinology, 2015, 61, 46.	1.3	2
309	Neuropsychological functioning in acromegaly: towards identification of modifiable factors to improve long-term care after remission. Endocrine, 2015, 50, 523-525.	1.1	2
310	Low sclerostin levels after long-term remission of acromegaly. Endocrine, 2022, 75, 228-238.	1.1	2
311	Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone. Lancet Diabetes and Endocrinology,the, 2020, 8, 348.	5.5	1
312	Cataplexy in a patient treated for prolactinoma: Case report. Vojnosanitetski Pregled, 2017, 74, 782-785.	0.1	1
313	ENDO-ERN ON RARE ENDOCRINE CONDITIONS: Endo-ERN in its fifth year: a pinch of care, science, curiosity and new horizons. Endocrine Connections, 2022, 11, .	0.8	1
314	Costs and Its Determinants in Pituitary Tumour Surgery. Frontiers in Endocrinology, 0, 13, .	1.5	1
315	Lanreotide AutogelÂ® in the Treatment of Acromegaly. Clinical Medicine Therapeutics, 2009, 1, CMT.S2150.	0.1	0
316	Loss-of-function mutations in the immunoglobulin superfamily member 1 gene (IGSF1) cause a novel, X-linked syndrome of central hypothyroidism and testicular enlargement. Lancet, The, 2013, 381, S15.	6.3	0
317	D05 Hypothalamic-pituitary-adrenal Axis Activity in Huntington's Disease And Its Association With Depressive Symptoms And Suicidality. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A33-A33.	0.9	0
318	Primary hypercortisolism and phaeochromocytoma next to, but not related to, each other. BMJ Case Reports, 2016, 2016, bcr2015213359.	0.2	0
319	Glucocorticoid Regulation of Neurocognitive and Neuropsychiatric Function. , 2017, , 27-41.		0
320	SUN-070 European Registries for Rare Endocrine Conditions (EuRRECa): Results from the Platform for E-reporting of Rare Endocrine Conditions (e-REC). Journal of the Endocrine Society, 2020, 4, .	0.1	0
321	Response to Letter to the Editor: â€œIGSF1 Deficiency Results in Human and Murine Somatotrope Neurosecretory Hyperfunctionâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2315-e2316.	1.8	0
322	Postoperative endocrinological follow-up. , 2021, , 439-446.		0
323	Body Surface Area Determines the Cortisol Production Rate in Obese Patients with Polycystic Ovary Syndrome and Obese Healthy Women.. , 2010, , P2-404-P2-404.		0
324	Trauma Severity, but Not Hypopituitarism, Affects Cognitive Function after Traumatic Brain Injury: A Multi-Center Study in the Netherlands.. , 2010, , P1-260-P1-260.		0

#	Article	IF	Citations
325	Endocriene tumoren. , 2011, , 513-555.		0
326	Response to the Letter by Lindholm, et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L66-L67.	1.8	0
327	Awareness & participation in rare disease registries within the European reference network on rare endocrine conditions (Endo-ERN). Endocrine Abstracts, 0, , .	0.0	0
328	Effects of Glucocorticoids on the Brain. , 2019, , 360-368.		0
329	Loss of glucocorticoid rhythm induces an osteoporotic phenotype in mice. Endocrine Abstracts, 0, , .	0.0	0
330	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0
331	Opioids and their endocrine effects: A systematic review and meta-analysis. Journal of Clinical Endocrinology and Metabolism, 0, , .	1.8	0